Intermittent sunitinib treatment is a feasible first-line approach in patients with renal cell carcinoma (RCC), providing a median progression-free survival duration of 37.6 months. Cyclic re-introduction of sunitinib after a treatment break might increase the duration of a response owing to resistance to tyrosine kinase inhibitors being largely dependent on reversible changes in gene expression. Biomarkers are needed to enable selection of the best candidates for intermittent treatment.
Refers to Ornstein, M. C. et al. A phase II study of intermittent sunitinib in previously untreated patients with metastatic renal cell carcinoma. J. Clin. Oncol.http://dx.doi.org/10.1200/JCO.2016.71.1184 (2017)